# A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers

> **NCT00002059** · NA · COMPLETED · sponsor: **Newport Pharmaceuticals International**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Inosine pranobex

## Key facts

- **NCT ID:** NCT00002059
- **Lead sponsor:** Newport Pharmaceuticals International
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002059, "A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00002059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*